Drug-device combination products in the twenty-first century: Epinephrine auto-injector development using human factors engineering

Expert Opinion on Drug Delivery

Volumn 12, Issue 5, 2015, Pages 751-762

  Edwards, Eric S ^a   Edwards, Evan T ^a   Simons, F Estelle R ^a,b   North, Robert ^c  

^a Kaléo Inc ^*  (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c LLC   (United States)

Author keywords

Adrenaline auto injector; Combination products; Epinephrine auto injector; Human factors engineering; Risk reduction; Safety

Indexed keywords

ADRENALIN;

BIOENGINEERING; DRUG DELIVERY SYSTEM; EPINEPHRINE AUTOINJECTOR; FOOD AND DRUG ADMINISTRATION; HAZARD ASSESSMENT; HUMAN; HUMAN FACTORS ENGINEERING; INFORMATION RETRIEVAL; INJECTION; PATIENT SAFETY; PRODUCT DEVELOPMENT; PRODUCT SAFETY; QUALITY CONTROL; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNINTENTIONAL INJECTION; ANAPHYLAXIS; REPRODUCIBILITY;

ANAPHYLAXIS; EPINEPHRINE; HUMAN ENGINEERING; HUMANS; INJECTIONS; REPRODUCIBILITY OF RESULTS;

EID: 84928328960     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.987660     Document Type: Review

References (49)

1. Jha AK, Prasopa-Plaizier N, Laizgoitia I, Bates DW. Research Priority Setting Working Group of the WHO Alliance for Patient Safety. Patient safety research: an overview of the global evidence. Qual Saf Health Care 2010;19:42-7
2. Ward JR, Clarkson PJ. An analysis of medical device-related errors: prevalence and possible solutions. J Med Eng Technol 2004;28:2-21
3. Leape LL. Error in medicine. JAMA 1994;272:1851-7
4. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7
5. Simons FER, Ardusso LR, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014;7:9
6. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010;126:477-80.e1-e42
7. Simons FER, Ardusso LR, Bilò MB, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. J Allergy Clin Immunol 2011;127:587-93.e1-e22
8. NIAID-Sponsored Expert Panel. Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010;126:S1-58
9. Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011;127:852-4
10. Human factors engineering-Design of medical devices. Association for the Advancement of Medical Instrumentation. American National Standard. ANSI/AAMI HE75. 2009. Available from: http://www.aami. org/publications/standards/HE75-Ch16-Access-Board.pdf [Last accessed 28 May 2014]
11. Medical devices; current good manufacturing practice (CGMP) final rule; quality system regulation. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. Last update October 2010. Available from: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/QualitySystemsRegulations/ucm230127. htm [Last accessed 28 May 2014]
12. CFR-Code of Federal Regulations Title 21-21CFR820.30. Design controls. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. September 2013. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=820.30 [Last accessed 28 May 2014]
13. Guidance for Industry and FDA Staff: Early development considerations for innovative combination products. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. September 2006. Available from: http://www.fda. gov/downloads/RegulatoryInformation/Guidances/ucm126054.pdf [Last accessed 28 May 2014]
14. Trautman KA. The FDA and worldwide quality system requirements guidebook for medical devices. Milwaukee, WI: ASQ Quality Press:1997. p. 151-2
15. Guidance for Industry and FDA Staff: Technical considerations for pen, jet, and related injectors intended for use with drugs and biological products. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. June 2013. Available from: http://www.fda. gov/downloads/RegulatoryInformation/Guidances/UCM147095.pdf [Last accessed 28 May 2014]
16. Draft Guidance for Industry and Food and Drug Administration Staff: Applying human factors and usability engineering to optimize medical device design. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. June 2011. Available from: http://www.fda. gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM259760.pdf [Last accessed 28 May 2014]
17. Fu M, Weick-Brady M, Tanno E. Medical devices in the home: a unique challenge for the FDA. Work 2012;41:361-5
18. Zhang J, Johnson TR, Patel VL, et al. Using usability heuristics to evaluate patient safety of medical devices. J Biomed Inform 2003;36:23-30
19. Gurses AP, Ozok AA, Pronovost PJ. Time to accelerate integration of human factors and ergonomics in patient safety. BMJ Qual Saf 2012;21:347-51
20. Warburton RN. Patient safety-how much is enough? Health Policy 2005;71:223-32
21. Lin L, Vicente KJ, Doyle DJ. Patient safety, potential adverse drug events, and medical device design: a human factors engineering approach. J Biomed Inform 2001;34:274-84
22. Price DB, Pearce L, Powell SR, et al. Handling and acceptability of the Easi-Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. Int J Clin Pract 1999;53:31-6
23. Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001;107:191-3
24. Gosbee LL. Nuts! I can't figure out how to use my life-saving epinephrine auto-injector!. Jt Comm J Qual Saf 2004;30:220-3
25. Simons FER, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009;124:301-6
26. Macadam C, Barnett J, Roberts G, et al. What factors affect the carriage of epinephrine auto-injectors by teenagers? Clin Transl Allergy 2012;2:3
27. Money AG, Barnett J, Kuljis J, Lucas J. Patient perceptions of epinephrine auto-injectors: exploring barriers to use. Scand J Caring Sci 2013;27:335-44
28. Simons FER, Edwards ES, Read EJ Jr, et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010;125:419-23
29. Arga M, Bakirtas A, Catal F, et al. Training of trainers on epinephrine autoinjector use. Pediatr Allergy Immunol 2011;22:590-3
30. Topal E, Bakirtas A, Yilmaz O, et al. A real-life study on acquired skills from using an adrenaline autoinjector. Int Arch Allergy Immunol 2013;160:301-6
31. Topal E, Bakirtas A, Yilmaz O, et al. When should we perform a repeat training on adrenaline auto-injector use for physician trainees? Allergol Immunopathol (Madr) 2013; published online 28 October 2013; doi:10.1016/j.aller.2013.07.008
32. Brown J, Tuthill D, Alfaham M, Spear E. A randomized maternal evaluation of epinephrine autoinjection devices. Pediatr Allergy Immunol 2013;24:173-7
33. Chad L, Ben-Shoshan M, Asai Y, et al. A majority of parents of children with peanut allergy fear using the epinephrine auto-injector. Allergy 2013;68:1605-9
34. Schwirtz A, Seeger H. Are adrenaline autoinjectors fit for purpose? A pilot study of the mechanical and injection performance characteristics of a cartridge-versus a syringe-based autoinjector. J Asthma Allergy 2010;3:159-67
35. Guerlain S, Hugine A, Wang L. A comparison of 4 epinephrine autoinjector delivery systems: usability and patient preference. Ann Allergy Asthma Immunol 2010;104:172-7
36. Guerlain S, Wang L, Hugine A. Intelliject's novel epinephrine autoinjector: sharps injury prevention validation and comparable analysis with EpiPen and Twinject. Ann Allergy Asthma Immunol 2010;105:480-4
37. Camargo CA Jr, Guana A, Wang S, Simons FER. Auvi-Q versus EpiPen: preferences of adults, caregivers, and children. J Allergy Clin Immunol Pract 2013;1:266-72
38. Edwards ES, Edwards ET, Gunn R, et al. Design validation and labeling comprehension study for a new epinephrine autoinjector. Ann Allergy Asthma Immunol 2013;110:189-93
39. Story MF. Human factors considerations for combination products. U.S. Food and Drug Administration. Presented at the 2011 RAPS, Indianapolis, IN, USA. 2011. Available from: http://www.fda. gov/downloads/MedicalDevices/DeviceRegulationandGuidance/HumanFactors/UCM282338.pdf [Last accessed 28 May 2014]
40. Noimark L, Wales J, Du Toit G, et al. The use of adrenaline autoinjectors by children and teenagers. Clin Exp Allergy 2012;42:284-92
41. EpiPen and EpiPen Jr auto-injector-important safety information on correct usage-for the public. Healthy Canadians. 2011. Available from: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/14096a-eng.php [Last accessed 28 May 2014]
42. Anonymous. Thumb accidentally injected despite EpiPen redesign. ISMP Medication Safety Alert! Nurse Advise-ERR 2011;8:3
43. Bakirtas A, Arga M, Catal F, et al. Make-up of the epinephrine autoinjector: the effect on its use by untrained users. Pediatr Allergy Immunol 2011;22:729-33
44. EpiPen epinephrine) Auto-Injector 0.3 mg and EpiPen Jr (epinephrine) Auto-Injector 0.15 mg. Prescribing information, Mylan Inc. Available from: https://www.epipen.com/-/media/files/epipen/prescribing%20information.pdf [Last accessed 28 May 2014]
45. Institute for Safe Medication Practices (ISMP). Acute Care-ISMP Medication Safety Alert. August 2011. Available from: https://www.ismp. org/newsletters/acutecare/issue.aspx?id=79 [Last accessed 23 September 2014]
46. Edwards ES, Gunn R, Simons FER, et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol 2013;111:132-7
47. Story MF. Human factors engineering of combination products and the FDA.U.S. Food and Drug Administration. Presented at the CaSSS CMC Strategy Forum. July 2012. Available from: http://www.fda. gov/downloads/MedicalDevices/DeviceRegulationandGuidance/HumanFactors/UCM320906.pdf [Last accessed 28 May 2014]
48. Kaye R. Human Factors/Usability for Medical Devices: An Historical Perspective. U.S. Food and Drug Administration. June 2011. Available from: http://www.fda. gov/downloads/MedicalDevices/DeviceRegulationandGuidance/HumanFactors/UCM260576.pdf [Last accessed 23 September 2014]
49. Inspections, Compliance, Enforcement, and Criminal Investigations. Warning Letter, 27 2014. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. Available from: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm385288.htm [Last accessed 23 September 2014]